The drug initially promotes proliferation and cytotoxicity of tumour-infiltrating cytotoxic T cells after one cycle of treatment, but after repeated cycles, the anti-tumour immune functions get impaired, with the release of immune-suppressive factors such as TGF-ß and IL-10 [27]. Here, IL10 is linked to neoplasm.